Aims

The integration of clinical trials into FCI is essential both as an end point of drug development and as a starting point for research on response and resistance mechanisms. The aim is to initiate such studies in close cooperation with the University  Cancer Center (UCT). UCT Frankfurt has been continuously working on the development of a comprehensive clinical research unit, which will be fully available to the FCI. The practical implementation of early translational studies at the FCI site is guaranteed.
Of particular importance to the FCI are the clinician scientists in Research Area 5, which are organized in multicenter study groups for therapy optimization. They assist the FCI project groups with questions of clinical relevance and cover a broad spectrum of indications (gastric, rectal, mammary and lung cancers, brain tumors, acute lymphocytic and myeloid leukemias, multiple myelomas, lymphomas). The study groups have developed important milestones to treat the respective disease, advise hospitals beyond the university clinics, and are essential multipliers and strategic partners in the clinical implementation of the FCI’s work and in planning the research strategy in the FCI.